AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35000455 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-Coated Balloons (DCB)
Number of subjects: 758
Study 35000455 — intervention group
Group type: COMPARATOR
Intervention: Drug-Eluting Stents (DES)
Number of subjects: 758
Study 33411845 — intervention group
Group type: EXPERIMENTAL
Intervention: Health behavior pattern 2 (alcoholic beverage and smoking habit)
Number of subjects: 71553
Study 33411845 — intervention group
Group type: EXPERIMENTAL
Intervention: Health behavior pattern 3 (ultra-processed food and screen time)
Number of subjects: 71553
Study 33411845 — intervention group
Group type: EXPERIMENTAL
Intervention: Health behavior pattern 1 (water, unprocessed and minimally processed food and physical activity)
Number of subjects: 71553
Study 33411845 — intervention group
Group type: EXPERIMENTAL
Intervention: Regularly purchasing snacks in the school cafeteria
Number of subjects: 71553
Study 33993205 — intervention group
Group type: EXPERIMENTAL
Intervention: ?‐3 carboxylic acid (CA)
Number of subjects: 13078
Study 33993205 — intervention group
Group type: COMPARATOR
Intervention: corn oil
Number of subjects: 13078
Study 36181071 — intervention group
Group type: EXPERIMENTAL
Intervention: High-pitch cervical CT (HP-CT)
Number of subjects: 95
Study 36181071 — intervention group
Group type: COMPARATOR
Intervention: Standard cervical CT (SD-CT)
Number of subjects: 95
Study 32525328 — intervention group
Group type: EXPERIMENTAL
Intervention: MI-based interactive message
Number of subjects: 805
Study 32525328 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninteractive motivational message
Number of subjects: 805
Study 32525328 — intervention group
Group type: COMPARATOR
Intervention: Control message (no motivational elements)
Number of subjects: 805
Study 35672833 — intervention group
Group type: EXPERIMENTAL
Intervention: 9-month regimen for rifampicin-resistant tuberculosis
Number of subjects: 0
Study 35672833 — intervention group
Group type: COMPARATOR
Intervention: 20-month regimen for rifampicin-resistant tuberculosis
Number of subjects: 0
Study 35672833 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental regimens including bedaquiline (Stage 2 of STREAM)
Number of subjects: 0
Study 32050305 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional barriers reported by participants
Number of subjects: 2360
Study 32050305 — intervention group
Group type: EXPERIMENTAL
Intervention: Cancer symptom awareness score
Number of subjects: 2360
Study 35978336 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-led telehealth intervention in Hyperlink 1
Number of subjects: 0
Study 35978336 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-led telehealth intervention in Hyperlink 3
Number of subjects: 0
Study 35978336 — intervention group
Group type: COMPARATOR
Intervention: Hyperlink 1
Number of subjects: 0
Study 35978336 — intervention group
Group type: COMPARATOR
Intervention: Hyperlink 3
Number of subjects: 0
Study 33544533 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical mask
Number of subjects: 297
Study 33544533 — intervention group
Group type: EXPERIMENTAL
Intervention: Respiratory mask
Number of subjects: 297
Study 32614875 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone call from a midwife offering choice between a visit for a pap smear or an HPV self-sampling test
Number of subjects: 10614
Study 32614875 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV self-sampling test only
Number of subjects: 10614
Study 32614875 — intervention group
Group type: COMPARATOR
Intervention: Routine procedure with a yearly invitation (Control)
Number of subjects: 10614
Study 32614875 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up after abnormality
Number of subjects: 10614
Study 32614875 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-attendees with study intervention
Number of subjects: 10614
Study 32614875 — intervention group
Group type: COMPARATOR
Intervention: Non-attendees without study intervention (Control)
Number of subjects: 10614
Study 36225762 — intervention group
Group type: EXPERIMENTAL
Intervention: Text4Hope intervention group (IG) receiving once-daily supportive text messages for 6 weeks
Number of subjects: 286
Study 36225762 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG) not receiving text messages
Number of subjects: 286
Study 36225762 — intervention group
Group type: EXPERIMENTAL
Intervention: Text4Hope intervention group (IG)
Number of subjects: 286
Study 35968725 — intervention group
Group type: EXPERIMENTAL
Intervention: Palmar grasp reflex stimulation during bathing
Number of subjects: 82
Study 35968725 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard tub bathing)
Number of subjects: 82
Study 32897310 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive systolic blood pressure reduction (goal, 110‐139 mm Hg)
Number of subjects: 999
Study 32897310 — intervention group
Group type: COMPARATOR
Intervention: Standard systolic blood pressure reduction (goal, 140‐179 mm Hg)
Number of subjects: 999
Study 32897310 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive systolic blood pressure reduction
Number of subjects: 999
Study 32897310 — intervention group
Group type: COMPARATOR
Intervention: Standard systolic blood pressure reduction
Number of subjects: 999
Study 36199051 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomechanical markers (e.g., flexion during loading)
Number of subjects: 0
Study 36199051 — intervention group
Group type: COMPARATOR
Intervention: X-ray grading (Kellgren-Lawrence grade)
Number of subjects: 0
Study 33913415 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracorporeal anastomosis (ICA)
Number of subjects: 100
Study 33913415 — intervention group
Group type: COMPARATOR
Intervention: Extracorporeal anastomosis (ECA)
Number of subjects: 100
Study 33913415 — intervention group
Group type: EXPERIMENTAL
Intervention: Both ICA and ECA
Number of subjects: 100
Study 32854623 — intervention group
Group type: EXPERIMENTAL
Intervention: Suburban CHCs
Number of subjects: 2404
Study 32854623 — intervention group
Group type: COMPARATOR
Intervention: Urban CHCs
Number of subjects: 2404
Study 32854623 — intervention group
Group type: COMPARATOR
Intervention: Rural CHCs
Number of subjects: 2404
Study 33837140 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive placebos (SHAM grades of 3 or more)
Number of subjects: 1494
Study 33837140 — intervention group
Group type: COMPARATOR
Intervention: Non-invasive placebo
Number of subjects: 1494
Study 35206449 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate–vigorous physical activity (MVPA)
Number of subjects: 100
Study 35206449 — intervention group
Group type: EXPERIMENTAL
Intervention: Screen time
Number of subjects: 100
Study 32207709 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard treatment complex (STC) + 5% brine electrophoresis by sinusoidal modulated currents, sage and sea baths
Number of subjects: 83
Study 32207709 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment complex (STC)
Number of subjects: 83
Study 35849214 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast infusion of 20% albumin (3 mL/kg over 30 min)
Number of subjects: 12
Study 35849214 — intervention group
Group type: COMPARATOR
Intervention: Slow infusion of 20% albumin (3 mL/kg over 120 min)
Number of subjects: 12
Study 35849214 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast infusion of 20% albumin
Number of subjects: 12
Study 35849214 — intervention group
Group type: COMPARATOR
Intervention: Slow infusion of 20% albumin
Number of subjects: 12
Study 33537000 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole (LE) 2.5mg/day
Number of subjects: 270
Study 33537000 — intervention group
Group type: COMPARATOR
Intervention: Clomiphene Citrate (CC) 50mg/day
Number of subjects: 270
Study 33537000 — intervention group
Group type: COMPARATOR
Intervention: Natural Cycle
Number of subjects: 270
Study 35962633 — intervention group
Group type: COMPARATOR
Intervention: E. sinica at 1% (CEa1)
Number of subjects: 0
Study 35962633 — intervention group
Group type: COMPARATOR
Intervention: E. sinica at 3% (CEa2)
Number of subjects: 0
Study 35962633 — intervention group
Group type: COMPARATOR
Intervention: E. sinica at 5% (CEa3)
Number of subjects: 0
Study 35962633 — intervention group
Group type: COMPARATOR
Intervention: Control treatment (CON)
Number of subjects: 0
Study 34103066 — intervention group
Group type: EXPERIMENTAL
Intervention: Taurine supplementation (30 mg/kg/day)
Number of subjects: 32
Study 34103066 — intervention group
Group type: COMPARATOR
Intervention: Standard Entera Meal
Number of subjects: 32
Study 32103160 — intervention group
Group type: EXPERIMENTAL
Intervention: 30% oral dextrose
Number of subjects: 169
Study 32103160 — intervention group
Group type: EXPERIMENTAL
Intervention: 30% oral dextrose and facilitated tucking
Number of subjects: 169
Study 32103160 — intervention group
Group type: COMPARATOR
Intervention: Facilitated tucking
Number of subjects: 169
Study 36401577 — intervention group
Group type: EXPERIMENTAL
Intervention: Amniotic membrane
Number of subjects: 34
Study 36401577 — intervention group
Group type: COMPARATOR
Intervention: Platelet-rich fibrin
Number of subjects: 34
Study 32844597 — intervention group
Group type: EXPERIMENTAL
Intervention: Three playful things
Number of subjects: 533
Study 32844597 — intervention group
Group type: EXPERIMENTAL
Intervention: Using playfulness in a new way
Number of subjects: 533
Study 32844597 — intervention group
Group type: EXPERIMENTAL
Intervention: Counting playfulness
Number of subjects: 533
Study 32844597 — intervention group
Group type: COMPARATOR
Intervention: Placebo condition
Number of subjects: 533
Study 36239405 — intervention group
Group type: EXPERIMENTAL
Intervention: Fulvestrant-Palbociclib (FP)
Number of subjects: 486
Study 36239405 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole-Palbociclib (LP)
Number of subjects: 486
Study 32615179 — intervention group
Group type: COMPARATOR
Intervention: Very early precut (group A)
Number of subjects: 303
Study 32615179 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary precut (group B)
Number of subjects: 303
Study 32376814 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity promoting program based on the IMB model
Number of subjects: 75
Study 32062862 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide extended release 2 mg
Number of subjects: 44
Study 32062862 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 34571011 — intervention group
Group type: EXPERIMENTAL
Intervention: Wii Fit rehabilitation program (30 minutes) in addition to standard physical therapy program (SPTP) (60 minutes), 3 sessions a week for 12 weeks.
Number of subjects: 34
Study 34571011 — intervention group
Group type: COMPARATOR
Intervention: Standard physical therapy program (SPTP) only, 3 sessions a week for 12 weeks.
Number of subjects: 34
Study 32586078 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitions in reserve (RIR)
Number of subjects: 14
Study 32586078 — intervention group
Group type: COMPARATOR
Intervention: Maximum effort (RM)
Number of subjects: 14
Study 35859360 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper body stretching (n = 15)
Number of subjects: 48
Study 35859360 — intervention group
Group type: COMPARATOR
Intervention: Lower body power training (n = 33)
Number of subjects: 48
Study 34480783 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline values of HRQoL, six-minute walking distance, Borg-score, coronary heart disease, SF-36 role-emotional
Number of subjects: 422
Study 34480783 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline values of Borg-score, six-minute walking distance, coronary heart disease, SF-36 vitality
Number of subjects: 422
Study 34480783 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline values of SF-36 physical functioning, HADS anxiety
Number of subjects: 422
Study 34480783 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline values of SF-36 vitality, presence of coronary heart disease
Number of subjects: 422
Study 34480783 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline values of HADS anxiety
Number of subjects: 422
Study 32331793 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatic epithelioid angiomyolipoma (HEAML)
Number of subjects: 66
Study 32331793 — intervention group
Group type: COMPARATOR
Intervention: Non-hepatitis B, non-hepatitis C hepatocellular carcinoma (NBNC‐HCC)
Number of subjects: 66
Study 34499903 — intervention group
Group type: EXPERIMENTAL
Intervention: AQUIRE training (intervention)
Number of subjects: 65
Study 34499903 — intervention group
Group type: COMPARATOR
Intervention: Local standard practices (control)
Number of subjects: 65
Study 33429174 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate nasal spray (2 puffs of 100 µg once daily in each nostril for 3 weeks) with olfactory training
Number of subjects: 100
Study 33429174 — intervention group
Group type: COMPARATOR
Intervention: Olfactory training only
Number of subjects: 100
Study 33429174 — intervention group
Group type: COMPARATOR
Intervention: Both groups (Mometasone and Control)
Number of subjects: 100
Study 35193903 — intervention group
Group type: EXPERIMENTAL
Intervention: Real taVNS
Number of subjects: 90
Study 35193903 — intervention group
Group type: COMPARATOR
Intervention: Sham taVNS
Number of subjects: 90
Study 33567890 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan (4 mg intravenous infusion over 10 min)
Number of subjects: 37
Study 33567890 — intervention group
Group type: COMPARATOR
Intervention: Placebo (intravenous infusion over 10 min)
Number of subjects: 37
Study 33567890 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan
Number of subjects: 37
Study 33567890 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 33122353 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental agents with single-agent activity classified as active
Number of subjects: 50
Study 33122353 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactive agents
Number of subjects: 50
Study 33122353 — intervention group
Group type: EXPERIMENTAL
Intervention: Agents without known single-agent activity (pooled inactive and indeterminate)
Number of subjects: 50
Study 33845669 — intervention group
Group type: EXPERIMENTAL
Intervention: Resiliency Group
Number of subjects: 92
Study 33845669 — intervention group
Group type: COMPARATOR
Intervention: Negative Psychosocial Effects Group
Number of subjects: 92
Study 32267878 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIPC)
Number of subjects: 60
Study 32267878 — intervention group
Group type: COMPARATOR
Intervention: Sham intervention
Number of subjects: 60
Study 35637106 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg caffeine capsule
Number of subjects: 18
Study 35637106 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsule
Number of subjects: 18
Study 33636217 — intervention group
Group type: EXPERIMENTAL
Intervention: numeric-calories message
Number of subjects: 3481
Study 33636217 — intervention group
Group type: EXPERIMENTAL
Intervention: PACE message
Number of subjects: 3481
Study 33636217 — intervention group
Group type: EXPERIMENTAL
Intervention: vague calorie message
Number of subjects: 3481
Study 33636217 — intervention group
Group type: COMPARATOR
Intervention: control message
Number of subjects: 3481
Study 33636217 — intervention group
Group type: EXPERIMENTAL
Intervention: All interventions
Number of subjects: 3481
Study 33636217 — intervention group
Group type: COMPARATOR
Intervention: control
Number of subjects: 3481
Study 32078486 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy (DAPT) with aspirin plus clopidogrel
Number of subjects: 4550
Study 32078486 — intervention group
Group type: COMPARATOR
Intervention: Aspirin alone
Number of subjects: 4550
Study 35073193 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral Transcutaneous Electrical Nerve Stimulation
Number of subjects: 0
Study 35971525 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-efficacy intervention (normal nursing + self-efficacy intervention)
Number of subjects: 140
Study 32352505 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant treatment with 4 cycles of nivolumab and doxorubicin, vinblastine, and dacarbazine (N-AVD)
Number of subjects: 109
Study 32352505 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential treatment with 4 doses of nivolumab, 2 cycles of N-AVD, and 2 cycles of AVD followed by 30-Gy involved-site radiotherapy
Number of subjects: 109
Study 32352505 — intervention group
Group type: COMPARATOR
Intervention: Nivolumab monotherapy (4 doses)
Number of subjects: 109
Study 35193902 — intervention group
Group type: EXPERIMENTAL
Intervention: SPEAKS intervention (weekly psychotherapy lasting nine to 12 months)
Number of subjects: 60
Study 33570488 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine agonists and clonazepam prescriptions
Number of subjects: 11466
Study 33570488 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative prescription dose of medication
Number of subjects: 11466
Study 32703776 — intervention group
Group type: EXPERIMENTAL
Intervention: Noxious cold-water immersion
Number of subjects: 40
Study 32703776 — intervention group
Group type: COMPARATOR
Intervention: Warm water
Number of subjects: 40
Study 32703776 — intervention group
Group type: COMPARATOR
Intervention: Warm water with voluntary suppression
Number of subjects: 40
Study 32703776 — intervention group
Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 40
Study 34807760 — intervention group
Group type: EXPERIMENTAL
Intervention: PLG0206 (0.05, 0.125, 0.25, 0.5, or 1 mg/kg)
Number of subjects: 48
Study 34807760 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 34807760 — intervention group
Group type: EXPERIMENTAL
Intervention: PLG0206 (0.05 to 1.0 mg/kg)
Number of subjects: 48
Study 36197728 — intervention group
Group type: EXPERIMENTAL
Intervention: Corrective exercises plus bracing
Number of subjects: 180
Study 36197728 — intervention group
Group type: EXPERIMENTAL
Intervention: Only bracing
Number of subjects: 180
Study 36197728 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 180
Study 34446057 — intervention group
Group type: EXPERIMENTAL
Intervention: gemcitabine plus S‐1 (GS)
Number of subjects: 100
Study 34446057 — intervention group
Group type: COMPARATOR
Intervention: gemcitabine plus nab‐paclitaxel (GA)
Number of subjects: 100
Study 32315823 — intervention group
Group type: EXPERIMENTAL
Intervention: Exclusion condition (received significantly fewer passes in Cyberball game)
Number of subjects: 0
Study 32315823 — intervention group
Group type: COMPARATOR
Intervention: Control condition (received an equal number of passes in Cyberball game)
Number of subjects: 0
Study 32315823 — intervention group
Group type: EXPERIMENTAL
Intervention: Both conditions (exclusion and control)
Number of subjects: 0
Study 33270835 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal Hexagon (IH) connection implants
Number of subjects: 49
Study 33270835 — intervention group
Group type: COMPARATOR
Intervention: Internal Conical (IC) connection implants
Number of subjects: 49
Study 36452957 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous wave EA
Number of subjects: 560
Study 36452957 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous wave TEAS
Number of subjects: 560
Study 36452957 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous wave TEAS + EA
Number of subjects: 560
Study 36452957 — intervention group
Group type: EXPERIMENTAL
Intervention: Dilatational wave EA
Number of subjects: 560
Study 36452957 — intervention group
Group type: EXPERIMENTAL
Intervention: Dilatational wave TEAS
Number of subjects: 560
Study 36452957 — intervention group
Group type: EXPERIMENTAL
Intervention: Dilatational wave TEAS + EA
Number of subjects: 560
Study 36452957 — intervention group
Group type: COMPARATOR
Intervention: Control (no EA or TEAS)
Number of subjects: 560
Study 36452957 — intervention group
Group type: EXPERIMENTAL
Intervention: All interventions
Number of subjects: 560
Study 33115821 — intervention group
Group type: EXPERIMENTAL
Intervention: Semaglutide
Number of subjects: 0
Study 33115821 — intervention group
Group type: COMPARATOR
Intervention: GLP-1RA comparators
Number of subjects: 0
Study 35280228 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation (50,000 IU)
Number of subjects: 129
Study 35280228 — intervention group
Group type: COMPARATOR
Intervention: Vitamin D3 supplementation (5,000 IU)
Number of subjects: 129
Study 35280228 — intervention group
Group type: EXPERIMENTAL
Intervention: Both doses of vitamin D3 supplementation
Number of subjects: 129
Study 35280228 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower dose (5,000 IU)
Number of subjects: 129
Study 35280228 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher dose (50,000 IU)
Number of subjects: 129
Study 32649502 — intervention group
Group type: EXPERIMENTAL
Intervention: Prediction model based on eight variables (maternal age, body mass index, gestational age, intrapartum magnesium sulfate for seizure prophylaxis, need for cervical ripening, prior cesarean delivery, cervical dilation, and effacement)
Number of subjects: 1357
Study 32649502 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal validation of the prediction model
Number of subjects: 1357
Study 35770374 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cannabis (0, 10 and 25 mg ∆9-THC)
Number of subjects: 21
Study 35770374 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaporized cannabis (0, 5 and 20 mg ∆9-THC)
Number of subjects: 21
Study 35770374 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cannabis administration
Number of subjects: 21
Study 35770374 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaporized cannabis administration
Number of subjects: 21
Study 35770374 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunoassays for ∆9-THC-COOH
Number of subjects: 21
Study 34661550 — intervention group
Group type: EXPERIMENTAL
Intervention: MiSAOS intelligent monitoring system
Number of subjects: 60
Study 34661550 — intervention group
Group type: COMPARATOR
Intervention: Standard management (Control)
Number of subjects: 60
Study 32443332 — intervention group
Group type: EXPERIMENTAL
Intervention: Jia Wei Liang Xue Xiao Feng San granules
Number of subjects: 72
Study 32443332 — intervention group
Group type: COMPARATOR
Intervention: Acitretin Capsule
Number of subjects: 72
Study 35331944 — intervention group
Group type: EXPERIMENTAL
Intervention: Early mobilisation using a Sara Combilizer®
Number of subjects: 0
Study 35331944 — intervention group
Group type: COMPARATOR
Intervention: Rest (no mobilisation)
Number of subjects: 0
Study 34647140 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensor-augmented pump (SAP) in predictive low glucose suspend (PLGS) mode
Number of subjects: 10
Study 34647140 — intervention group
Group type: COMPARATOR
Intervention: Low glucose suspend (LGS) mode
Number of subjects: 10